Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or Lymphoma
NCT ID: NCT03821363
Last Updated: 2019-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
206 participants
INTERVENTIONAL
2018-12-13
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
NCT02836834
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
NCT03852823
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
NCT03692520
A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors
NCT05499715
A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors
NCT03312842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose group
SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
SCT-I10A
Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
Middle dose group
SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
SCT-I10A
Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
High dose group
SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
SCT-I10A
Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SCT-I10A
Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males or females. Aged 18 to 75 years old;
* Life expectancy≥12 weeks before starting treatment (clinical assessment);
* With an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1;
* Histologically or cytologically confirmed advanced solid tumor or lymphoma;
* Advanced solid tumor or lymphoma with standard treatment failed or no effective therapy;
* According to RECIST 1.1 or Lugano 2014 criteria, patients must have at least one measurable lesion that can be accurately assessed;
* Adequate organ and bone marrow function as defined below:
Absolute neutrophil count (ANC) greater than/equal to 1.5×l09/L; Platelets greater than/equal to 75×109/L; Hemoglobin greater than/equal to 80g/L; Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than/equal to 2.5 times ULN, or less than/equal to 5 times ULN if known liver metastases; Total bilirubin less than/equal to 1.5 times ULN; Serum creatinine less than/equal to 1.5 times ULN or Ccr\>50ml/min; Thyroid stimulating hormone (TSH) hormone levels less than/equal to ULN.
Exclusion Criteria
* Patients have been treated with anti-PD-L1 and anti-PD-1 antibody;
* Patients are currently enrolled in other research devices or in research drugs, or less than 4 weeks from other research drugs or devices;
* Within 4 weeks prior to the first dose of study drug, patients have received anti-tumor drugs (such as chemotherapy, endocrine therapy, targeted therapy, immune therapy, tumor embolization). Within 6 weeks prior to the first dose of study drug, patients have been treated with biological products, nitrosourea or mitomycin C;
* Within 2 weeks prior to the first dose of study drug, patients have received corticosteroids or other immunosuppressive agents;
* Within 4 weeks prior to the first dose of study drug, patients have received live attenuated vaccine (LAV), or who planned to use LAV during the study period;
* Within 4 weeks prior to the first dose of study drug, patients have received major surgery, or had wounds, ulcers or fractures that haven't healed;
* Prior to the first dose of study drug, patients had toxicity due to previous anti-tumor treatment, which hasn't return to Grade 0-1 according to the NCI CTCAEv4.03;
* Patient with cerebrospinal meningitis metastasis or central nervous system metastasis with untreated or uncontrolled with other treatment;
* Patients with an active, known or suspected autoimmune disease or a history of autoimmune disease;
* Patients with a history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
* Within 6 months prior to study, patients had uncontrolled concurrent diseases, including but not limited to acute myocardial infarction, unstable angina pectoris, stroke, or transient ischemic attack, congestive heart failure (NYHA, greater than II), left ventricular ejection fraction (LVEF) \<50%, and with related heart disease. Patients with chronic or acute disease, psychological or psychiatric disorders, laboratory abnormalities which may affect subject compliance and outcomes in this clinical study;
* Patients with HIV, active hepatitis B (HBV DNA≥104 copies/ml) or active hepatitis C (HCV RNA≥103 copies/ml), etc.;
* Patients who have interstitial lung disease, such as interstitial pneumonia, pulmonary fibrosis, or CT or MRI reminder ILD.
* Patients with clinical symptoms, required clinical intervention or stable time less than 4 weeks of serous cavity effusion (such as pleural effusion and ascites);
* Patients with other primary malignancies;
* Pregnant or lactating women;
* Patients who were not willing to accept effective contraceptive measures during treatment and within 6 months after treatment;
* Subjects who are considered not suitable for the study by investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinocelltech Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Fifth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCT-I10A-X101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.